/Stocks/AMGN
▲ Cast your call
AMGNAmgen Inc. · NASDAQ · Healthcare
$339.30+$1.88 · +0.56%
MKT 184.73B

Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Sector
Healthcare
Industry
Drug Manufacturers - General
Phone
805 447 1000
Headquarters
One Amgen Center Drive
Thousand Oaks, CA, 91320-1799
United States
Full-Time Employees
31,500

Key Metrics

P/E Ratio (TTM)
23.81
Forward P/E
14.57
Price to Book
20.09
Beta
0.44
Profit Margin
20.96%
Gross Margin
71.44%
Return on Equity
101.32%
Return on Assets
8.35%
Earnings Growth
4.40%
Revenue Growth
5.80%
Dividend Yield
299.00%
Dividend Rate
$10.08

Financial Health

Total Cash
$12.04B
Total Debt
$57.32B
Debt to Equity
623.75
Current Ratio
1.26
Free Cash Flow
$7.44B
Operating Cash Flow
$10.76B

Analyst Recommendations

Target Price (Mean)
$352.23
Target High
$427.00
Target Low
$200.00
Recommendation
buy
Analyst Coverage
30 Analysts

Trading Ideas

Related Stocks

Will AMGN Beat Earnings? AI Prediction next earnings | CallTheBeat